Original language | English (US) |
---|---|
Pages (from-to) | E201-E204 |
Journal | American journal of hematology |
Volume | 97 |
Issue number | 6 |
DOIs | |
State | Published - Jun 1 2022 |
ASJC Scopus subject areas
- Hematology
Cite this
- APA
- Standard
- Harvard
- Vancouver
- Author
- BIBTEX
- RIS
In: American journal of hematology, Vol. 97, No. 6, 01.06.2022, p. E201-E204.
Research output: Contribution to journal › Letter › peer-review
}
TY - JOUR
T1 - Dismal outcomes of patients with relapsed/refractory Philadelphia chromosome-negative B-cell acute lymphoblastic leukemia after failure of both inotuzumab ozogamicin and blinatumomab
AU - Short, Nicholas J.
AU - Macaron, Walid
AU - Konopleva, Marina
AU - Ravandi, Farhad
AU - Jain, Nitin
AU - Issa, Ghayas C.
AU - Kadia, Tapan
AU - Sasaki, Koji
AU - Kebriaei, Partow
AU - Yilmaz, Musa
AU - Thompson, Philip A.
AU - Takahashi, Koichi
AU - Abbas, Hussein A.
AU - Wierda, William G.
AU - Garris, Rebecca
AU - Kantarjian, Hagop M.
AU - Jabbour, Elias
N1 - Funding Information: K12 Paul Calabresi Clinical Oncology Scholar Award and the American Society of Hematology; MD Anderson Cancer Center, Grant/Award Number: CA016672 Funding Information: Nicholas J. Short has served as consultant for Takeda Oncology, Amgen, AstraZeneca, Novartis, Jazz Pharmaceutics, and Pfizer and reports receiving research grants from Takeda Oncology, Astellas Pharma, Stemline Therapeutics, and Xencor. Elias Jabbour has received research funding and consulting fees from Amgen and Pfizer. The other authors have no relevant conflicts of interest to disclose.
PY - 2022/6/1
Y1 - 2022/6/1
UR - http://www.scopus.com/inward/record.url?scp=85126344345&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85126344345&partnerID=8YFLogxK
U2 - 10.1002/ajh.26526
DO - 10.1002/ajh.26526
M3 - Letter
C2 - 35266566
AN - SCOPUS:85126344345
SN - 0361-8609
VL - 97
SP - E201-E204
JO - American journal of hematology
JF - American journal of hematology
IS - 6
ER -